Product Description
Prasugrel, trade name Effient, is an investigational new antiplatelet drug currently under review for clinical use by the Food and Drug Administration. It is a thienopyridine analog with a structure similar to that of clopidogrel and ticlopidine. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/18923235/)
Mechanisms of Action: P2Y12 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lithuania | Luxembourg | Malta | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Acute Coronary Syndrome | Coronary Thrombosis | Myocardial Infarction | Thrombosis | Angina, Stable | Angina, Unstable
Known Adverse Events: Injuries/wounds Unspecified
Company: Cosette Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: Daiichi Sankyo
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, Colombia, Croatia, Germany, Hungary, India, Ireland, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Spain, United Kingdom, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: COVID-19|Coronary Artery Disease|Influenza, Human|Pneumonia
Phase 2: Atherosclerosis
Phase 1: Healthy Volunteers|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2023-507015-35-00 | P3 |
Not yet recruiting |
Coronary Artery Disease |
2029-07-30 |
|
| ANGIODAPT | P3 |
Active, not recruiting |
Coronary Artery Disease |
2029-07-21 |
|
| REMAP-CAP | P3 |
Recruiting |
Pneumonia|Influenza, Human|COVID-19 |
2026-02-01 |
|
| SYNIVUS-DAPT | P2 |
Active, not recruiting |
Coronary Artery Disease|Atherosclerosis |
2021-12-31 |